SAN ANTONIO — Several types of anti-obesity medications (AOMs), including glucagon-like peptide 1s (GLP-1s), are associated ...

That’s according to a clinical trial conducted in 11 countries — the first of its kind to show that one of the wave of ...

Popular GLP-1 drugs are already known to have many benefits, but scientists continue to explore what else they — and their ...

Popular weight-loss drug Wegovy maker Novo Nordisk expects high demand and acceptance for its anti-obesity drug, when ...

A new study examining a large sample of privately insured patients with obesity found that use of drugs such as Ozempic and Wegovy as anti-obesity medications more than doubled from 2022 to 2023.

With a gain of more than 531% over the last 12 months, shares of Viking Therapeutics (NASDAQ: VKTX) are a hot commodity, to ...

Viking Therapeutics reported clinical trial data on Sunday, which excited some investors. Despite signs that Viking's ...

Obesity treatment shifts from surgery to drugs as bariatric procedures decline by 25.6% and GLP-1 receptor agonist use jumps ...

Surging demand for a new generation of highly effective anti-obesity medications is creating interest in compounded versions of these medications.

Weight-loss drugs, particularly newer options like GLP-1 receptor agonists, are revolutionising the treatment of obesity and ...

Eli Lilly’s stock heads for biggest selloff in more than three years after sales of anti-obesity drugs Mounjaro and Zepbound ...

Drugs Ozempic and Wegovy have slimmed down Hollywood stars — and millions of non-celebrities worldwide— while adding great ...